 SOUTH SAN FRANCISCO, Calif. and CAMBRIDGE, England, June 22, 2021 PRNewswire -- Today Pionyr Immunotherapeutics, Inc., a company developing first-in-class antibody therapeutics that increase the bodys anti-tumor immunity and Abcam AIM: ABC NASDAQ: ABCM, a global innovator in life science reagents and tools, announced the extension of their collaboration with a new commercial licensing agreement to support the progression of PY314, the first to the clinic of Pionyrs compounds. 